nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—HSD3B2—prostate cancer	0.087	0.391	CbGaD
Medroxyprogesterone Acetate—breast cancer—Estrone—prostate cancer	0.0629	0.245	CpDpCtD
Medroxyprogesterone Acetate—breast cancer—Estradiol valerate/Dienogest—prostate cancer	0.0629	0.245	CpDpCtD
Medroxyprogesterone Acetate—AKR1C3—prostate cancer	0.0482	0.217	CbGaD
Medroxyprogesterone Acetate—breast cancer—Estradiol—prostate cancer	0.0477	0.185	CpDpCtD
Medroxyprogesterone Acetate—breast cancer—Conjugated Estrogens—prostate cancer	0.0477	0.185	CpDpCtD
Medroxyprogesterone Acetate—Testosterone—Abiraterone—prostate cancer	0.0411	0.264	CrCrCtD
Medroxyprogesterone Acetate—breast cancer—Ethinyl Estradiol—prostate cancer	0.0362	0.14	CpDpCtD
Medroxyprogesterone Acetate—SHBG—prostate cancer	0.025	0.112	CbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.0231	0.149	CrCrCtD
Medroxyprogesterone Acetate—AR—Nilutamide—prostate cancer	0.0223	0.0992	CbGbCtD
Medroxyprogesterone Acetate—AR—Bicalutamide—prostate cancer	0.0223	0.0992	CbGbCtD
Medroxyprogesterone Acetate—AR—prostate cancer	0.022	0.0986	CbGaD
Medroxyprogesterone Acetate—AR—Flutamide—prostate cancer	0.0185	0.0822	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Estramustine—prostate cancer	0.0179	0.0797	CbGbCtD
Medroxyprogesterone Acetate—Testosterone—Estramustine—prostate cancer	0.0171	0.11	CrCrCtD
Medroxyprogesterone Acetate—ESR1—prostate cancer	0.0169	0.076	CbGaD
Medroxyprogesterone Acetate—SHBG—Estrone—prostate cancer	0.016	0.071	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—prostate cancer	0.0149	0.0669	CbGaD
Medroxyprogesterone Acetate—SHBG—Ethinyl Estradiol—prostate cancer	0.0142	0.0633	CbGbCtD
Medroxyprogesterone Acetate—Testosterone—Estrone—prostate cancer	0.0136	0.0871	CrCrCtD
Medroxyprogesterone Acetate—ESR1—Estrone—prostate cancer	0.0115	0.0514	CbGbCtD
Medroxyprogesterone Acetate—Methyltestosterone—Ethinyl Estradiol—prostate cancer	0.0113	0.0724	CrCrCtD
Medroxyprogesterone Acetate—ESR1—Ethinyl Estradiol—prostate cancer	0.0103	0.0458	CbGbCtD
Medroxyprogesterone Acetate—Testosterone—Estradiol—prostate cancer	0.0103	0.066	CrCrCtD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—prostate cancer	0.00946	0.0421	CbGbCtD
Medroxyprogesterone Acetate—SHBG—Estradiol—prostate cancer	0.00917	0.0408	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—prostate cancer	0.00863	0.0388	CbGaD
Medroxyprogesterone Acetate—AR—Estradiol—prostate cancer	0.00767	0.0341	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Conjugated Estrogens—prostate cancer	0.00755	0.0336	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Estradiol—prostate cancer	0.00663	0.0295	CbGbCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Prednisone—prostate cancer	0.00656	0.0422	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Nilutamide—prostate cancer	0.00488	0.0217	CbGbCtD
Medroxyprogesterone Acetate—Hydrocortamate—Prednisone—prostate cancer	0.00482	0.031	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Prednisone—prostate cancer	0.00467	0.03	CrCrCtD
Medroxyprogesterone Acetate—Prednicarbate—Prednisone—prostate cancer	0.00453	0.0291	CrCrCtD
Medroxyprogesterone Acetate—NR3C1—Prednisone—prostate cancer	0.0042	0.0187	CbGbCtD
Medroxyprogesterone Acetate—Fludrocortisone—Prednisone—prostate cancer	0.00406	0.0261	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Abiraterone—prostate cancer	0.00404	0.018	CbGbCtD
Medroxyprogesterone Acetate—Methyltestosterone—Prednisone—prostate cancer	0.00396	0.0254	CrCrCtD
Medroxyprogesterone Acetate—Fluorometholone—Prednisone—prostate cancer	0.00377	0.0242	CrCrCtD
Medroxyprogesterone Acetate—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00377	0.0168	CbGbCtD
Medroxyprogesterone Acetate—Methylprednisolone—Prednisone—prostate cancer	0.00352	0.0226	CrCrCtD
Medroxyprogesterone Acetate—CYP2C9—Nilutamide—prostate cancer	0.0034	0.0151	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Bicalutamide—prostate cancer	0.0034	0.0151	CbGbCtD
Medroxyprogesterone Acetate—Hydrocortisone—Prednisone—prostate cancer	0.00331	0.0213	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Cabazitaxel—prostate cancer	0.00299	0.0133	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00261	0.0116	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Estrone—prostate cancer	0.00204	0.00907	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Bicalutamide—prostate cancer	0.00198	0.0088	CbGbCtD
Medroxyprogesterone Acetate—SHBG—semen—prostate cancer	0.00184	0.115	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Estramustine—prostate cancer	0.00184	0.00819	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Estradiol—prostate cancer	0.00168	0.00747	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Abiraterone—prostate cancer	0.00164	0.0073	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Flutamide—prostate cancer	0.00164	0.0073	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Capecitabine—prostate cancer	0.00155	0.00687	CbGbCtD
Medroxyprogesterone Acetate—AR—penis—prostate cancer	0.00139	0.0866	CbGeAlD
Medroxyprogesterone Acetate—AR—semen—prostate cancer	0.00132	0.0825	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Cabazitaxel—prostate cancer	0.00121	0.0054	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Estrone—prostate cancer	0.00119	0.00527	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Estradiol—prostate cancer	0.00117	0.00521	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—prostate cancer	0.0011	0.00488	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00106	0.0047	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Conjugated Estrogens—prostate cancer	0.000776	0.00345	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Mitoxantrone—prostate cancer	0.000705	0.00314	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Estradiol—prostate cancer	0.000681	0.00303	CbGbCtD
Medroxyprogesterone Acetate—NR3C1—urine—prostate cancer	0.000668	0.0417	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—urine—prostate cancer	0.000663	0.0414	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—testis—prostate cancer	0.000641	0.04	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—prostate cancer	0.00062	1	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—prostate gland—prostate cancer	0.000614	0.0383	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Prednisone—prostate cancer	0.000586	0.00261	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—seminal vesicle—prostate cancer	0.000519	0.0324	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—urine—prostate cancer	0.000505	0.0316	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—prostate cancer	0.000464	0.029	CbGeAlD
Medroxyprogesterone Acetate—SHBG—prostate gland—prostate cancer	0.000461	0.0288	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—prostate cancer	0.000445	0.00198	CbGbCtD
Medroxyprogesterone Acetate—PGR—prostate gland—prostate cancer	0.000416	0.026	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—urethra—prostate cancer	0.000411	0.0257	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Docetaxel—prostate cancer	0.000407	0.00181	CbGbCtD
Medroxyprogesterone Acetate—AR—prostate gland—prostate cancer	0.000331	0.0207	CbGeAlD
Medroxyprogesterone Acetate—ESR1—prostate gland—prostate cancer	0.000325	0.0203	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—bone marrow—prostate cancer	0.000316	0.0198	CbGeAlD
Medroxyprogesterone Acetate—PGR—epithelium—prostate cancer	0.000305	0.0191	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—prostate cancer	0.000303	0.00135	CbGbCtD
Medroxyprogesterone Acetate—AR—seminal vesicle—prostate cancer	0.00028	0.0175	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—testis—prostate cancer	0.00027	0.0169	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—prostate cancer	0.000243	0.0152	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—prostate gland—prostate cancer	0.00024	0.015	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—prostate cancer	0.000239	0.0149	CbGeAlD
Medroxyprogesterone Acetate—SHBG—bone marrow—prostate cancer	0.000238	0.0148	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—prostate cancer	0.000226	0.0141	CbGeAlD
Medroxyprogesterone Acetate—AR—urethra—prostate cancer	0.000222	0.0138	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—prostate cancer	0.000222	0.0138	CbGeAlD
Medroxyprogesterone Acetate—SHBG—testis—prostate cancer	0.000203	0.0127	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—seminal vesicle—prostate cancer	0.000203	0.0127	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—prostate cancer	0.000196	0.0122	CbGeAlD
Medroxyprogesterone Acetate—PGR—testis—prostate cancer	0.000183	0.0114	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—renal system—prostate cancer	0.000183	0.0114	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—prostate cancer	0.000176	0.011	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—prostate cancer	0.000163	0.0102	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—urethra—prostate cancer	0.000161	0.01	CbGeAlD
Medroxyprogesterone Acetate—AR—testis—prostate cancer	0.000146	0.00911	CbGeAlD
Medroxyprogesterone Acetate—ESR1—testis—prostate cancer	0.000143	0.00894	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—prostate cancer	0.000133	0.00829	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—renal system—prostate cancer	0.000124	0.00772	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bone marrow—prostate cancer	0.000124	0.00772	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—testis—prostate cancer	0.000118	0.00737	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—prostate cancer	0.000106	0.0066	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—testis—prostate cancer	0.000106	0.0066	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—prostate cancer	0.000104	0.00648	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—AR—prostate cancer	9.54e-05	0.0568	CrCbGaD
Medroxyprogesterone Acetate—Cyproterone acetate—CYP19A1—prostate cancer	7.98e-05	0.0475	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—prostate cancer	7.66e-05	0.00478	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—NR3C1—prostate cancer	6.47e-05	0.0385	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—CYP17A1—prostate cancer	5.49e-05	0.0327	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—ANXA1—prostate cancer	5.39e-05	0.0321	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP3A43—prostate cancer	5.25e-05	0.0313	CrCbGaD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—prostate cancer	4.81e-05	0.0286	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—COMT—prostate cancer	4.48e-05	0.0267	CrCbGaD
Medroxyprogesterone Acetate—Prednicarbate—NR3C1—prostate cancer	4.17e-05	0.0248	CrCbGaD
Medroxyprogesterone Acetate—Drospirenone—AR—prostate cancer	3.98e-05	0.0237	CrCbGaD
Medroxyprogesterone Acetate—Eplerenone—CYP3A5—prostate cancer	3.77e-05	0.0224	CrCbGaD
Medroxyprogesterone Acetate—Fludrocortisone—AR—prostate cancer	3.75e-05	0.0223	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—SHBG—prostate cancer	3.53e-05	0.021	CrCbGaD
Medroxyprogesterone Acetate—Medrysone—NR3C1—prostate cancer	3.49e-05	0.0208	CrCbGaD
Medroxyprogesterone Acetate—Flurandrenolide—NR3C1—prostate cancer	3.37e-05	0.02	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—AR—prostate cancer	3.34e-05	0.0199	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortamate—NR3C1—prostate cancer	3.26e-05	0.0194	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—SHBG—prostate cancer	3.23e-05	0.0192	CrCbGaD
Medroxyprogesterone Acetate—Cortisone acetate—NR3C1—prostate cancer	3.21e-05	0.0191	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—AR—prostate cancer	3.09e-05	0.0184	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—NR3C1—prostate cancer	3.09e-05	0.0184	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—SHBG—prostate cancer	2.85e-05	0.017	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—AR—prostate cancer	2.83e-05	0.0169	CrCbGaD
Medroxyprogesterone Acetate—Fludrocortisone—NR3C1—prostate cancer	2.54e-05	0.0151	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP17A1—prostate cancer	2.52e-05	0.015	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—AR—prostate cancer	2.5e-05	0.0149	CrCbGaD
Medroxyprogesterone Acetate—Fluorometholone—NR3C1—prostate cancer	2.45e-05	0.0146	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—SLC22A3—prostate cancer	2.41e-05	0.0143	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—prostate cancer	2.38e-05	0.0142	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—NR3C1—prostate cancer	2.37e-05	0.0141	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—SLC22A3—prostate cancer	2.28e-05	0.0135	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—SHBG—prostate cancer	2.15e-05	0.0128	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—NR3C1—prostate cancer	2.1e-05	0.0125	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP19A1—prostate cancer	2.09e-05	0.0125	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—NR3C1—prostate cancer	1.92e-05	0.0114	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortamate—CYP3A4—prostate cancer	1.89e-05	0.0112	CrCbGaD
Medroxyprogesterone Acetate—Cortisone acetate—CYP3A4—prostate cancer	1.86e-05	0.0111	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—SHBG—prostate cancer	1.75e-05	0.0104	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1B1—prostate cancer	1.75e-05	0.0104	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—SLC22A1—prostate cancer	1.73e-05	0.0103	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—CYP3A5—prostate cancer	1.71e-05	0.0102	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—SHBG—prostate cancer	1.65e-05	0.00984	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1B1—prostate cancer	1.65e-05	0.00984	CrCbGaD
Medroxyprogesterone Acetate—Eplerenone—CYP3A4—prostate cancer	1.63e-05	0.00971	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—SLC22A1—prostate cancer	1.63e-05	0.00971	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—AR—prostate cancer	1.53e-05	0.00913	CrCbGaD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—prostate cancer	1.53e-05	0.00912	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—AR—prostate cancer	1.45e-05	0.00863	CrCbGaD
Medroxyprogesterone Acetate—Fluorometholone—CYP3A4—prostate cancer	1.42e-05	0.00845	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP3A5—prostate cancer	1.39e-05	0.00829	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—CYP3A4—prostate cancer	1.37e-05	0.00817	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP2A6—prostate cancer	1.35e-05	0.00803	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP3A5—prostate cancer	1.32e-05	0.00784	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—NR3C1—prostate cancer	1.28e-05	0.0076	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP19A1—prostate cancer	1.21e-05	0.00722	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ESR1—prostate cancer	1.18e-05	0.00703	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—NR3C1—prostate cancer	1.04e-05	0.00619	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP3A4—prostate cancer	9.82e-06	0.00585	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP2C19—prostate cancer	9.48e-06	0.00564	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1A1—prostate cancer	9.44e-06	0.00562	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP2C19—prostate cancer	8.96e-06	0.00533	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1A1—prostate cancer	8.93e-06	0.00531	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—CYP3A4—prostate cancer	7.4e-06	0.00441	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP3A4—prostate cancer	6.03e-06	0.00359	CrCbGaD
Medroxyprogesterone Acetate—Dermatitis—Mitoxantrone—prostate cancer	5.94e-06	7.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.94e-06	7.93e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mitoxantrone—prostate cancer	5.91e-06	7.89e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Capecitabine—prostate cancer	5.9e-06	7.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Docetaxel—prostate cancer	5.9e-06	7.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Prednisone—prostate cancer	5.87e-06	7.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Prednisone—prostate cancer	5.87e-06	7.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Docetaxel—prostate cancer	5.86e-06	7.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—prostate cancer	5.85e-06	7.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Prednisone—prostate cancer	5.85e-06	7.81e-05	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—prostate cancer	5.83e-06	7.79e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.83e-06	7.78e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Docetaxel—prostate cancer	5.81e-06	7.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Docetaxel—prostate cancer	5.8e-06	7.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Prednisone—prostate cancer	5.8e-06	7.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—prostate cancer	5.79e-06	7.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—prostate cancer	5.78e-06	7.72e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—prostate cancer	5.77e-06	7.71e-05	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—prostate cancer	5.76e-06	7.69e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.75e-06	7.68e-05	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—prostate cancer	5.75e-06	7.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Docetaxel—prostate cancer	5.74e-06	7.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—prostate cancer	5.73e-06	7.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—prostate cancer	5.73e-06	7.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Capecitabine—prostate cancer	5.71e-06	7.63e-05	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—CYP3A4—prostate cancer	5.7e-06	0.00339	CrCbGaD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—prostate cancer	5.69e-06	7.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Capecitabine—prostate cancer	5.67e-06	7.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Docetaxel—prostate cancer	5.67e-06	7.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—prostate cancer	5.66e-06	7.56e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—prostate cancer	5.64e-06	7.54e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Docetaxel—prostate cancer	5.63e-06	7.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—prostate cancer	5.63e-06	7.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—prostate cancer	5.63e-06	7.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Capecitabine—prostate cancer	5.63e-06	7.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Prednisone—prostate cancer	5.62e-06	7.51e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Prednisone—prostate cancer	5.62e-06	7.51e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Docetaxel—prostate cancer	5.62e-06	7.51e-05	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—prostate cancer	5.62e-06	7.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—prostate cancer	5.61e-06	7.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mitoxantrone—prostate cancer	5.6e-06	7.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—prostate cancer	5.59e-06	7.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Prednisone—prostate cancer	5.59e-06	7.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—prostate cancer	5.58e-06	7.45e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Docetaxel—prostate cancer	5.58e-06	7.45e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Capecitabine—prostate cancer	5.56e-06	7.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—prostate cancer	5.55e-06	7.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—prostate cancer	5.55e-06	7.41e-05	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Prednisone—prostate cancer	5.53e-06	7.39e-05	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—prostate cancer	5.52e-06	7.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Prednisone—prostate cancer	5.51e-06	7.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Prednisone—prostate cancer	5.49e-06	7.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Capecitabine—prostate cancer	5.49e-06	7.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—prostate cancer	5.47e-06	7.31e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Prednisone—prostate cancer	5.46e-06	7.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Capecitabine—prostate cancer	5.45e-06	7.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Capecitabine—prostate cancer	5.44e-06	7.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Prednisone—prostate cancer	5.44e-06	7.26e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—prostate cancer	5.42e-06	7.24e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—prostate cancer	5.42e-06	7.23e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Capecitabine—prostate cancer	5.4e-06	7.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—prostate cancer	5.39e-06	7.2e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—prostate cancer	5.39e-06	7.2e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Docetaxel—prostate cancer	5.37e-06	7.18e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—prostate cancer	5.37e-06	7.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Prednisone—prostate cancer	5.36e-06	7.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—prostate cancer	5.35e-06	7.15e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—prostate cancer	5.34e-06	7.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Docetaxel—prostate cancer	5.33e-06	7.12e-05	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—prostate cancer	5.32e-06	7.1e-05	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—prostate cancer	5.31e-06	7.09e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—prostate cancer	5.29e-06	7.06e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—prostate cancer	5.28e-06	7.05e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—prostate cancer	5.23e-06	6.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—prostate cancer	5.21e-06	6.96e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Capecitabine—prostate cancer	5.2e-06	6.95e-05	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—prostate cancer	5.2e-06	6.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—prostate cancer	5.19e-06	6.93e-05	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—prostate cancer	5.18e-06	6.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—prostate cancer	5.17e-06	6.91e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Capecitabine—prostate cancer	5.16e-06	6.9e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—prostate cancer	5.16e-06	6.89e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Docetaxel—prostate cancer	5.15e-06	6.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Docetaxel—prostate cancer	5.15e-06	6.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—prostate cancer	5.14e-06	6.86e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Prednisone—prostate cancer	5.12e-06	6.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Prednisone—prostate cancer	5.09e-06	6.79e-05	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—prostate cancer	5.06e-06	6.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Prednisone—prostate cancer	5.05e-06	6.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—prostate cancer	5.02e-06	6.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Capecitabine—prostate cancer	5.02e-06	6.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—prostate cancer	5e-06	6.68e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Capecitabine—prostate cancer	4.99e-06	6.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Capecitabine—prostate cancer	4.99e-06	6.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—prostate cancer	4.99e-06	6.66e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—prostate cancer	4.99e-06	6.66e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—prostate cancer	4.99e-06	6.66e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—prostate cancer	4.98e-06	6.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—prostate cancer	4.95e-06	6.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Prednisone—prostate cancer	4.95e-06	6.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—prostate cancer	4.95e-06	6.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—prostate cancer	4.94e-06	6.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—prostate cancer	4.92e-06	6.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—prostate cancer	4.91e-06	6.56e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—prostate cancer	4.89e-06	6.54e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Prednisone—prostate cancer	4.89e-06	6.53e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—prostate cancer	4.88e-06	6.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—prostate cancer	4.86e-06	6.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Prednisone—prostate cancer	4.85e-06	6.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—prostate cancer	4.84e-06	6.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—prostate cancer	4.84e-06	6.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—prostate cancer	4.83e-06	6.45e-05	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—prostate cancer	4.82e-06	6.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Prednisone—prostate cancer	4.81e-06	6.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Docetaxel—prostate cancer	4.8e-06	6.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—prostate cancer	4.79e-06	6.4e-05	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—prostate cancer	4.76e-06	6.36e-05	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—prostate cancer	4.74e-06	6.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Docetaxel—prostate cancer	4.68e-06	6.25e-05	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—prostate cancer	4.67e-06	6.24e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—prostate cancer	4.66e-06	6.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Capecitabine—prostate cancer	4.65e-06	6.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Prednisone—prostate cancer	4.63e-06	6.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—prostate cancer	4.63e-06	6.18e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Docetaxel—prostate cancer	4.61e-06	6.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—prostate cancer	4.61e-06	6.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Prednisone—prostate cancer	4.6e-06	6.14e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—prostate cancer	4.59e-06	6.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—prostate cancer	4.59e-06	6.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—prostate cancer	4.59e-06	6.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—prostate cancer	4.58e-06	6.12e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—prostate cancer	4.57e-06	6.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.56e-06	6.09e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—prostate cancer	4.53e-06	6.05e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Capecitabine—prostate cancer	4.53e-06	6.05e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—prostate cancer	4.5e-06	6.01e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—prostate cancer	4.49e-06	5.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—prostate cancer	4.48e-06	5.98e-05	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—prostate cancer	4.47e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Prednisone—prostate cancer	4.47e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Capecitabine—prostate cancer	4.47e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Docetaxel—prostate cancer	4.46e-06	5.96e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Prednisone—prostate cancer	4.45e-06	5.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Prednisone—prostate cancer	4.45e-06	5.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—prostate cancer	4.43e-06	5.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—prostate cancer	4.41e-06	5.89e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—prostate cancer	4.4e-06	5.87e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—prostate cancer	4.4e-06	5.87e-05	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—prostate cancer	4.38e-06	5.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—prostate cancer	4.37e-06	5.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—prostate cancer	4.33e-06	5.78e-05	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—prostate cancer	4.32e-06	5.77e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Capecitabine—prostate cancer	4.32e-06	5.77e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—prostate cancer	4.31e-06	5.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Docetaxel—prostate cancer	4.31e-06	5.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—prostate cancer	4.31e-06	5.75e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—prostate cancer	4.29e-06	5.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—prostate cancer	4.27e-06	5.71e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—prostate cancer	4.25e-06	5.68e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—prostate cancer	4.25e-06	5.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—prostate cancer	4.25e-06	5.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—prostate cancer	4.25e-06	5.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—prostate cancer	4.23e-06	5.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.22e-06	5.63e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—prostate cancer	4.19e-06	5.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—prostate cancer	4.19e-06	5.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Capecitabine—prostate cancer	4.17e-06	5.58e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—prostate cancer	4.15e-06	5.55e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Docetaxel—prostate cancer	4.15e-06	5.54e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Prednisone—prostate cancer	4.14e-06	5.53e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Docetaxel—prostate cancer	4.11e-06	5.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—prostate cancer	4.11e-06	5.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Docetaxel—prostate cancer	4.11e-06	5.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—prostate cancer	4.1e-06	5.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Docetaxel—prostate cancer	4.08e-06	5.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—prostate cancer	4.07e-06	5.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—prostate cancer	4.07e-06	5.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—prostate cancer	4.04e-06	5.4e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Prednisone—prostate cancer	4.03e-06	5.39e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Capecitabine—prostate cancer	4.01e-06	5.36e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.01e-06	5.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—prostate cancer	4e-06	5.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—prostate cancer	3.99e-06	5.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—prostate cancer	3.98e-06	5.32e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Capecitabine—prostate cancer	3.98e-06	5.32e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Prednisone—prostate cancer	3.98e-06	5.31e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—prostate cancer	3.98e-06	5.31e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Capecitabine—prostate cancer	3.98e-06	5.31e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—prostate cancer	3.97e-06	5.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Capecitabine—prostate cancer	3.96e-06	5.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—prostate cancer	3.95e-06	5.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—prostate cancer	3.95e-06	5.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—prostate cancer	3.93e-06	5.25e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—prostate cancer	3.92e-06	5.24e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—prostate cancer	3.91e-06	5.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—prostate cancer	3.88e-06	5.18e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Docetaxel—prostate cancer	3.87e-06	5.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—prostate cancer	3.87e-06	5.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Prednisone—prostate cancer	3.85e-06	5.14e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—prostate cancer	3.82e-06	5.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—prostate cancer	3.8e-06	5.08e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—prostate cancer	3.8e-06	5.07e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—prostate cancer	3.79e-06	5.06e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—prostate cancer	3.76e-06	5.02e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Capecitabine—prostate cancer	3.75e-06	5.01e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Prednisone—prostate cancer	3.72e-06	4.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.71e-06	4.95e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—prostate cancer	3.68e-06	4.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—prostate cancer	3.65e-06	4.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—prostate cancer	3.63e-06	4.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—prostate cancer	3.62e-06	4.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—prostate cancer	3.62e-06	4.83e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—prostate cancer	3.6e-06	4.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—prostate cancer	3.58e-06	4.78e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Prednisone—prostate cancer	3.58e-06	4.78e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Prednisone—prostate cancer	3.55e-06	4.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Prednisone—prostate cancer	3.54e-06	4.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—prostate cancer	3.54e-06	4.72e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Prednisone—prostate cancer	3.52e-06	4.71e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.51e-06	4.69e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—prostate cancer	3.51e-06	4.69e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—prostate cancer	3.49e-06	4.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—prostate cancer	3.48e-06	4.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—prostate cancer	3.48e-06	4.64e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—prostate cancer	3.48e-06	4.64e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—prostate cancer	3.35e-06	4.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Prednisone—prostate cancer	3.34e-06	4.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—prostate cancer	3.33e-06	4.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—prostate cancer	3.24e-06	4.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—prostate cancer	3.23e-06	4.32e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—prostate cancer	3.22e-06	4.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—prostate cancer	3.22e-06	4.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—prostate cancer	3.16e-06	4.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—prostate cancer	3.11e-06	4.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—prostate cancer	3.01e-06	4.02e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—prostate cancer	3e-06	4e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—prostate cancer	2.92e-06	3.9e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—prostate cancer	2.91e-06	3.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—prostate cancer	2.88e-06	3.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—prostate cancer	2.8e-06	3.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—prostate cancer	2.78e-06	3.72e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—prostate cancer	2.77e-06	3.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—prostate cancer	2.77e-06	3.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—prostate cancer	2.76e-06	3.68e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—prostate cancer	2.69e-06	3.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Epirubicin—prostate cancer	2.61e-06	3.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—prostate cancer	2.59e-06	3.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—prostate cancer	2.57e-06	3.43e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—prostate cancer	2.56e-06	3.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—prostate cancer	2.55e-06	3.41e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—prostate cancer	2.42e-06	3.23e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—UMPS—prostate cancer	9.01e-07	1.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MDM2—prostate cancer	8.99e-07	1.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SERPINE1—prostate cancer	8.96e-07	1.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.89e-07	1.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SRC—prostate cancer	8.88e-07	1.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—prostate cancer	8.86e-07	1.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LPL—prostate cancer	8.86e-07	1.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC5A5—prostate cancer	8.85e-07	1.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LDHB—prostate cancer	8.83e-07	1.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SERPINE1—prostate cancer	8.82e-07	1.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PDGFRB—prostate cancer	8.78e-07	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CB—prostate cancer	8.75e-07	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP3A5—prostate cancer	8.67e-07	1.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—prostate cancer	8.65e-07	1.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP2E1—prostate cancer	8.65e-07	1.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HPGDS—prostate cancer	8.63e-07	1.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2C19—prostate cancer	8.58e-07	1.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—prostate cancer	8.57e-07	1.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ITGB3—prostate cancer	8.55e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NQO1—prostate cancer	8.55e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—prostate cancer	8.55e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TH—prostate cancer	8.43e-07	1.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—prostate cancer	8.4e-07	1.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA3—prostate cancer	8.37e-07	1.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—UCP3—prostate cancer	8.37e-07	1.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PDHA1—prostate cancer	8.37e-07	1.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TCN2—prostate cancer	8.37e-07	1.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTT1—prostate cancer	8.37e-07	1.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ACHE—prostate cancer	8.37e-07	1.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	8.37e-07	1.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP3A4—prostate cancer	8.34e-07	1.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB3—prostate cancer	8.3e-07	1.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	8.29e-07	1.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR2—prostate cancer	8.28e-07	1.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2A6—prostate cancer	8.28e-07	1.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.24e-07	1.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—prostate cancer	8.21e-07	1.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1B1—prostate cancer	8.2e-07	1.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—prostate cancer	8.08e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C3—prostate cancer	8.05e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—prostate cancer	8.04e-07	1.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—prostate cancer	8.03e-07	1.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PRKACB—prostate cancer	8.01e-07	1.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSD3B1—prostate cancer	7.99e-07	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC22A3—prostate cancer	7.99e-07	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—prostate cancer	7.96e-07	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—prostate cancer	7.95e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TGFB1—prostate cancer	7.94e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GGT1—prostate cancer	7.94e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP17A1—prostate cancer	7.92e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—prostate cancer	7.88e-07	1.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—prostate cancer	7.83e-07	1.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NCOA1—prostate cancer	7.82e-07	1.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.82e-07	1.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—prostate cancer	7.79e-07	1.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—prostate cancer	7.75e-07	1.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP19A1—prostate cancer	7.71e-07	1.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA4—prostate cancer	7.66e-07	1.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TBXAS1—prostate cancer	7.66e-07	1.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HIF1A—prostate cancer	7.6e-07	1.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—prostate cancer	7.6e-07	1.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1A—prostate cancer	7.57e-07	1.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—prostate cancer	7.56e-07	1.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOA2—prostate cancer	7.55e-07	1.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA2—prostate cancer	7.46e-07	1.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—RXRA—prostate cancer	7.44e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LEP—prostate cancer	7.42e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCG5—prostate cancer	7.37e-07	1.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SULT1A1—prostate cancer	7.37e-07	1.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—prostate cancer	7.36e-07	1.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—prostate cancer	7.36e-07	1.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CAV1—prostate cancer	7.35e-07	1.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—prostate cancer	7.27e-07	1.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.23e-07	1.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EP300—prostate cancer	7.21e-07	1.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC5A5—prostate cancer	7.2e-07	1.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA1—prostate cancer	7.2e-07	1.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—COMT—prostate cancer	7.16e-07	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—prostate cancer	7.13e-07	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.12e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAT2—prostate cancer	7.12e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTO1—prostate cancer	7.12e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2E1—prostate cancer	7.04e-07	1.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ITPR1—prostate cancer	7.02e-07	1.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SRC—prostate cancer	7.01e-07	1.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NQO1—prostate cancer	6.96e-07	1.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—BAD—prostate cancer	6.92e-07	1.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.9e-07	1.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TH—prostate cancer	6.86e-07	1.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLCB2—prostate cancer	6.83e-07	1.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.83e-07	1.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LRP2—prostate cancer	6.83e-07	1.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—prostate cancer	6.83e-07	1.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.81e-07	1.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP3A4—prostate cancer	6.79e-07	1.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—prostate cancer	6.76e-07	1.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—prostate cancer	6.76e-07	1.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.75e-07	1.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CG—prostate cancer	6.7e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APC—prostate cancer	6.7e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—prostate cancer	6.7e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—P4HB—prostate cancer	6.69e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1B1—prostate cancer	6.67e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMS—prostate cancer	6.63e-07	1.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGF—prostate cancer	6.62e-07	1.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IRS1—prostate cancer	6.62e-07	1.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—prostate cancer	6.6e-07	1.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTM1—prostate cancer	6.55e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—prostate cancer	6.54e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC22A1—prostate cancer	6.51e-07	1.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GGT1—prostate cancer	6.46e-07	1.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—LPL—prostate cancer	6.43e-07	1.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GSK3B—prostate cancer	6.43e-07	1.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOA1—prostate cancer	6.36e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SULT2A1—prostate cancer	6.35e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INS—prostate cancer	6.34e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—prostate cancer	6.28e-07	1.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP19A1—prostate cancer	6.27e-07	1.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TGFB1—prostate cancer	6.27e-07	1.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MED12—prostate cancer	6.24e-07	1.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1A1—prostate cancer	6.21e-07	1.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CREBBP—prostate cancer	6.21e-07	1.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GNG5—prostate cancer	6.19e-07	1.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ERCC2—prostate cancer	6.16e-07	1.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—prostate cancer	6.14e-07	1.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1—prostate cancer	6.13e-07	1.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—RXRA—prostate cancer	6.05e-07	1.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—prostate cancer	5.98e-07	1.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA3—prostate cancer	5.97e-07	1.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAP2K1—prostate cancer	5.93e-07	1.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CD—prostate cancer	5.89e-07	1.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.89e-07	1.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—COMT—prostate cancer	5.83e-07	1.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SERPINE1—prostate cancer	5.82e-07	1.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—prostate cancer	5.8e-07	1.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—prostate cancer	5.8e-07	1.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—prostate cancer	5.79e-07	1.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ITPR1—prostate cancer	5.71e-07	1.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HPGDS—prostate cancer	5.69e-07	1.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARA—prostate cancer	5.68e-07	1.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—prostate cancer	5.67e-07	1.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.66e-07	1.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGF2—prostate cancer	5.64e-07	1.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.61e-07	1.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—prostate cancer	5.58e-07	1.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOS3—prostate cancer	5.56e-07	1.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ACHE—prostate cancer	5.52e-07	1.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTT1—prostate cancer	5.52e-07	1.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—prostate cancer	5.52e-07	1.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.46e-07	1.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JAK2—prostate cancer	5.4e-07	1.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMS—prostate cancer	5.39e-07	1.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CAV1—prostate cancer	5.34e-07	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTM1—prostate cancer	5.33e-07	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—prostate cancer	5.33e-07	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.31e-07	1.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PRKACB—prostate cancer	5.28e-07	1.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MDM2—prostate cancer	5.28e-07	1.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—LPL—prostate cancer	5.23e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.23e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—prostate cancer	5.2e-07	1.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—prostate cancer	5.16e-07	1.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CB—prostate cancer	5.13e-07	1.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—prostate cancer	5.1e-07	1.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.1e-07	1.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1A1—prostate cancer	5.06e-07	1.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ERCC2—prostate cancer	5.01e-07	1.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA2—prostate cancer	4.98e-07	1.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—prostate cancer	4.93e-07	1.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CG—prostate cancer	4.87e-07	1.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—prostate cancer	4.82e-07	1.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.75e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—prostate cancer	4.72e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—prostate cancer	4.72e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—prostate cancer	4.71e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—prostate cancer	4.71e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.64e-07	1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARA—prostate cancer	4.62e-07	9.97e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—INS—prostate cancer	4.61e-07	9.93e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—prostate cancer	4.6e-07	9.9e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NQO1—prostate cancer	4.59e-07	9.89e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—prostate cancer	4.55e-07	9.81e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TH—prostate cancer	4.52e-07	9.75e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CREBBP—prostate cancer	4.51e-07	9.72e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—prostate cancer	4.46e-07	9.62e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1A—prostate cancer	4.45e-07	9.58e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—prostate cancer	4.44e-07	9.56e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.4e-07	9.48e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—prostate cancer	4.36e-07	9.39e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CAV1—prostate cancer	4.35e-07	9.37e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CD—prostate cancer	4.28e-07	9.22e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GGT1—prostate cancer	4.26e-07	9.18e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EP300—prostate cancer	4.23e-07	9.12e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA1—prostate cancer	4.2e-07	9.05e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.15e-07	8.95e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.14e-07	8.91e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SRC—prostate cancer	4.11e-07	8.87e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NOS3—prostate cancer	4.04e-07	8.71e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—prostate cancer	4.01e-07	8.63e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—RXRA—prostate cancer	3.99e-07	8.6e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—prostate cancer	3.97e-07	8.55e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.96e-07	8.53e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—prostate cancer	3.93e-07	8.47e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—prostate cancer	3.87e-07	8.35e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—COMT—prostate cancer	3.85e-07	8.29e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—prostate cancer	3.83e-07	8.25e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ITPR1—prostate cancer	3.77e-07	8.12e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—INS—prostate cancer	3.75e-07	8.08e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CB—prostate cancer	3.73e-07	8.04e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—prostate cancer	3.69e-07	7.96e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—prostate cancer	3.69e-07	7.94e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TGFB1—prostate cancer	3.68e-07	7.93e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CREBBP—prostate cancer	3.67e-07	7.91e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—prostate cancer	3.61e-07	7.77e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMS—prostate cancer	3.56e-07	7.67e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTM1—prostate cancer	3.52e-07	7.58e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CD—prostate cancer	3.48e-07	7.5e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—LPL—prostate cancer	3.45e-07	7.44e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—prostate cancer	3.41e-07	7.34e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.33e-07	7.19e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ERCC2—prostate cancer	3.31e-07	7.13e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NOS3—prostate cancer	3.29e-07	7.08e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—prostate cancer	3.22e-07	6.94e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—prostate cancer	3.13e-07	6.74e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—prostate cancer	3.11e-07	6.7e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—EP300—prostate cancer	3.07e-07	6.62e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARA—prostate cancer	3.05e-07	6.57e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CB—prostate cancer	3.03e-07	6.54e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—prostate cancer	3.03e-07	6.52e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—prostate cancer	3.01e-07	6.48e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CAV1—prostate cancer	2.87e-07	6.18e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—prostate cancer	2.77e-07	5.97e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—prostate cancer	2.62e-07	5.65e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.61e-07	5.63e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—prostate cancer	2.56e-07	5.51e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—EP300—prostate cancer	2.5e-07	5.39e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—INS—prostate cancer	2.47e-07	5.33e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CREBBP—prostate cancer	2.42e-07	5.22e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.3e-07	4.95e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—prostate cancer	2.27e-07	4.9e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NOS3—prostate cancer	2.17e-07	4.67e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CB—prostate cancer	2e-07	4.31e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—prostate cancer	1.98e-07	4.27e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—prostate cancer	1.86e-07	4e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.85e-07	3.99e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—prostate cancer	1.73e-07	3.73e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—EP300—prostate cancer	1.65e-07	3.55e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—prostate cancer	1.51e-07	3.26e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.22e-07	2.63e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—prostate cancer	9.96e-08	2.15e-06	CbGpPWpGaD
